ClinicalTrials.gg
CompletedNCT05326412AERIFY-3Updated Aug 31, 2026Results posted

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

A Phase 2 interventional study of Itepekimab SAR440340 in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 23 sites in 7 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Enrollment
12th of 12
49 · median 937
Started
2022
the only one that year
Phase 2
2 of 15
none open now
Registered
6th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 2 in phase 2, and was the 6th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.

This study consisted of participants who had been on a standard-of-care (SoC) mono (long-acting β2-agonist [LABA]) or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to Screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to Screening (Visit 1) and during the screening period. Participants would stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD (AECOPD).

Part A would consist of participants who were former smokers with COPD; Part B would consist of participants who were current smokers with COPD.

The total study duration for each part (Part A and Part B) was approximately 36 weeks:

  • 4-week screening period
  • 12-week treatment period
  • 20-week followup period
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 40 to 70 years of age inclusive
  • Physician diagnosis of for at least 1 year (based on the Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition).
  • Smoking history of ≥10 pack-years

    • For former smokers: Participants who reported that they were not currently smoking, and smoking cessation must had occurred ≥6 months prior to Screening (Visit 1) with an intention to quit permanently.
    • For current smokers (not eligible for Part A): Participants who reported that they are currently smoking tobacco (participant smoked at least 5 cigarettes per day on average during the past 7 days) at Screening (Visit 1) and at Baseline, and who were not currently participating in, or planning to initiate, a smoking cessation intervention at Screening (Visit 1) or during the screening period.
  • Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year before screening in a participant in whom other causes of chronic cough [eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] had been excluded).
  • Documented or self-reported history of exacerbation having had ≥1 moderate or severe exacerbation within the 5 years prior to Screening (Visit 1), with at least 1 exacerbation treated with systemic :

    • Moderate exacerbations were defined as an acute worsening of respiratory symptoms that required either systemic corticosteroids (intramuscular [IM], intravenous [IV], or oral) and/or antibiotics.
    • Severe exacerbations were defined as AECOPD that required hospitalization or observation for >24 hours in emergency department/urgent care facility.
  • Participants treated with SoC controller therapy for ≥3 months before Screening (Visit 1) and at a stable dose and regimen of controller therapy for at least 1 month before the screening visit AND during the screening period, including either: triple therapy with LAMA + LABA + ICS or double therapy with ICS + LABA or LABA + LAMA or ICS + LAMA, or monotherapy with LABA or LAMA.
  • Participants who had received appropriate vaccination according to local recommendations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), administered a minimum of 1 week prior to Screening (Visit 1).
  • (BMI) ≥18 kg/m2
  • A female participant was eligible to participate if she was not pregnant, not breastfed, and at least one of the following conditions applies:

    • Not a women of (WOCBP) or
    • A WOCBP who agreed to follow the guidance during the intervention period and for at least 20 weeks after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis or previously confirmed diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines unless asthma resolved before 18 years of age and has not recurred.
  • For former smokers (Parts A): Active smoking or vaping of any products (eg, nicotine, tetrahydrocannabinol [THC]) within 6 months prior to Screening (Visit 1) or during the screening period. For current smokers (Part B): vaping of any products (eg, nicotine, THC) within 6 months prior to Screening (Visit 1) or during the screening period.
  • Participants who were expected to be regularly exposed to environmental (ie, 'second hand') tobacco smoke in an indoor setting during the screening or treatment periods (former smokers only).
  • new abnormal (ECG) within 6 months before or at Screening (Visit 1) that might affect the participant's participation in the study.
  • Clinically significant and current pulmonary disease other than , eg, sarcoidosis, interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α1 anti-trypsin deficiency, or another diagnosed pulmonary disease.
  • Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe pulmonary hypertension.
  • Participants who required more than 2 L/min of long-term treatment with oxygen at rest. Participants who used up to 4L/min of supplemental oxygen during exercise might enroll. Oxygen during sleep was allowed.
  • Hypercapnia that required bi-level positive airway pressure (BiPAP).
  • Moderate or severe exacerbation of COPD (AECOPD) within 8 weeks prior to Screening (Visit 1) or during the screening period.
  • Prior history of pneumonectomy, lobectomy, segmentectomy, or therapeutic bronchoscopy procedure (including bronchoscopic volume reduction). Note: Prior history of surgical lung or wedge resection were not exclusion criteria.
  • Any surgery or major procedures (including those requiring conscious sedation) planned to occur during the study. Minor skin procedures were allowed.
  • Unstable ischemic heart disease, including acute myocardial infarction within 1 year before Screening (Visit 1), or unstable angina within 6 months before Screening (Visit 1) or during the screening period.
  • Cardiac arrhythmias, including paroxysmal (eg, intermittent) atrial fibrillation. Participants with isolated premature ventricular contractions (PVCs) or premature atrial contractions (PACs) might be considered for inclusion.
  • Cardiomyopathy, as defined by Stage III-IV () cardiac failure, or other relevant cardiovascular disorder that that might affect the participant's participation in the study.
  • Any underlying disease required the use of prophylaxis for endocarditis.
  • Uncontrolled hypertension (ie, systolic blood pressure [BP] >180 mm Hg or diastolic BP >110 mm Hg with or without use of antihypertensive therapy).
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who were at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette Guérin (BCG)-vaccination within 12 weeks before Screening (Visit 1).
  • History of (HIV) infection or positive HIV 1/2 serology at Screening (Visit 1).
  • Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or contact with known exposure to COVID19 at Screening (Visit 1) or during the screening period; known history of COVID19 infection within 6 weeks before Screening (Visit 1); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 12 months before Screening (Visit 1); participants who had a COVID-19 infection before Screening (Visit 1) who had not yet sufficiently recovered to participate in the procedures of a clinical trial.
  • Evidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 6 weeks before Screening (Visit 1) or during the screening period, significant viral infections within 6 weeks before Screening (Visit 1) or during the screening period that might not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment).
  • Participants with active disease or participants taking therapy for autoimmune disease (eg, rheumato arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis).
  • History of within 5 years before Screening (Visit 1), or during the screening period, except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
  • Symptomatic herpes zoster within 3 months prior to screening.
  • Previous use of Itepekimab.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Itepekimab

    This arm includes participants from 2 populations: Part A-former smokers and Part B-current smokers. Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks

    Drug: Itepekimab SAR440340

Interventions

  • Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous

    Also known as: REGN3500

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

    The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

  2. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

    The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

  3. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

    The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

Secondary outcomes

  1. Change From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12

    The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated eosinophil-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

  2. Change From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12

    The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated mast cell-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

  3. Change From Baseline to Week 12 in Blood Eosinophil Count

    Blood samples were collected at specified timepoints to assess change in blood eosinophil count. Baseline was defined as the last available value before first dose of study treatment.

    Time frame: Baseline (Week 0) and Week 12

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Event of Special Interests (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Permanent Treatment Discontinuation

    An AE was defined as any untoward medical occurrence in participant or clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. An AE of special interest (AESI) was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAEs were defined as any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. TEAEs were defined as AEs that developed, worsened or became serious during TE period (from first study treatment administration up to end of study).

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  5. Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology During the Treatment-emergent Period

    Blood samples were collected to determine the PCSA in hematology during the TE period (from the first treatment administration up to the end of study). Here, Hb = hemoglobin; g/L = grams per liter; M = male; F = female; v/v= volume by volume; LC = leukocyte count; NB = non-black; B = black; ULN = upper limit of normal and EO = eosinophils. Only parameters in which any participant had abnormality are reported.

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  6. Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry During the Treatment-emergent Period

    Blood samples were collected to determine the PCSA in chemistry during the TE period (first treatment administration up to the end of study). Here, mmol/L = millimoles/liter; LLN = lower limit of normal; mg/L = milligrams/liter and mcmol/L = micromoles/liter. Only parameters in which any participant had abnormality are reported.

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  7. Number of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period

    Urine samples were collected to determine the PCSA in urine during the TE period (from the first treatment administration up to the end of study).

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  8. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs During the Treatment-emergent Period

    Participants were examined to determine the PCSA in vital signs during the TE period (from the first treatment administration up to the end of study). Here, SSBP = sitting systolic blood pressure; mmHg = millimeters of mercury; DFB = decrease from baseline and IFB = increase from baseline. Only parameters in which any participant had abnormality are reported.

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  9. Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) During the Treatment-emergent Period

    Single 12-lead ECGs were obtained to determine PCSA during the TE period (from the first treatment administration up to the end of study). Here, QTcB= QT interval corrected by Bazett's formula and QTcF= QT interval corrected by Fridericia formula. Only parameters in which any participant had abnormality are reported.

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  10. Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab

    Blood samples were collected to evaluate antibodies to itepekimab in serum. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.

    Time frame: From first dose of study treatment administration (Week 0) up to end of study, 32 weeks

  11. Serum Concentrations of Functional Itepekimab

    Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

    Time frame: Pre-dose at Weeks 0, 4, 12 and 32

07

Results

Posted Aug 31, 2026

Participant flow

This study was conducted at 23 sites in 7 countries. A total of 102 participants were screened between 19 May 2022 and 07 November 2024 of which 53 were screen failures due to not meeting eligibility criteria. A total of 49 participants with chronic obstructive pulmonary disease (COPD) were enrolled in 2 groups (Part A: Former smokers and Part B: Current smokers) to receive itepekimab in this study.

Participant flow — Overall Study
MilestonePart A: Former SmokersPart B: Current Smokers
Started2524
Enrolled and treated2324
Completed2324
Not completed20
Withdrew: Enrolled but not treated20

Outcome measures

PrimaryChange From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Median · score on a scale
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
score on a scalePart A: Former SmokersPart B: Current Smokers
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 120.691 (-2.17 to 1.84)0.526 (-0.74 to 2.53)
PrimaryChange From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Median · score on a scale
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
score on a scalePart A: Former SmokersPart B: Current Smokers
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 120.534 (-0.60 to 1.05)0.270 (-1.00 to 1.63)
PrimaryChange From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12

The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). The gene signatures are derived from the genes differentially expressed in endobronchial biopsies, bronchial brushings, and nasal brushings of former smokers. The NES in current smokers, at baseline and at Week 12, are calculated based on the gene signatures of former smokers. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Median · score on a scale
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12
score on a scalePart A: Former SmokersPart B: Current Smokers
Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12-0.051 (-1.26 to 0.94)0.190 (-0.60 to 1.34)
SecondaryChange From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12

The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated eosinophil-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Median · score on a scale
Change From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12
score on a scalePart A: Former SmokersPart B: Current Smokers
Change From Baseline in Interleukin-33 (IL-33) Treated Eosinophil-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12-0.095 (-1.28 to 1.43)-0.006 (-2.29 to 0.34)
SecondaryChange From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12

The NES provides an indication of the difference in gene expression levels for a particular individual before and after treatment for a defined set of genes (or signature). IL-33 treated mast cell-associated gene signature is used to evaluate NES of endobronchial biopsies of former and current smokers, at baseline and Week 12. Change in NES from baseline indicates that the gene signature is differentially regulated in response to itepekimab, with up- and down-regulated genes changing in their expected directions. No predetermined directionality has been established for this score; therefore, a higher or lower NES does not indicate a better or worse outcome. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Median · score on a scale
Change From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12
score on a scalePart A: Former SmokersPart B: Current Smokers
Change From Baseline in Interleukin-33 Treated Mast Cell-associated Normalized Enrichment Score in Endobronchial Biopsies at Week 12-0.327 (-1.44 to 2.28)-0.044 (-2.10 to 1.00)
SecondaryChange From Baseline to Week 12 in Blood Eosinophil Count

Blood samples were collected at specified timepoints to assess change in blood eosinophil count. Baseline was defined as the last available value before first dose of study treatment.

Time frame:
Baseline (Week 0) and Week 12
Reported as:
Mean · 10^9 cells/liter
Change From Baseline to Week 12 in Blood Eosinophil Count
10^9 cells/literPart A: Former SmokersPart B: Current Smokers
Change From Baseline to Week 12 in Blood Eosinophil Count-0.06 ± 0.13-0.04 ± 0.11
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Event of Special Interests (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Permanent Treatment Discontinuation

An AE was defined as any untoward medical occurrence in participant or clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. An AE of special interest (AESI) was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAEs were defined as any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. TEAEs were defined as AEs that developed, worsened or became serious during TE period (from first study treatment administration up to end of study).

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Event of Special Interests (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Permanent Treatment Discontinuation
ParticipantsPart A: Former SmokersPart B: Current Smokers
TEAEs1817
TEAESIs10
TESAEs12
TEAEs leading to permanent study treatment discontinuation10
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology During the Treatment-emergent Period

Blood samples were collected to determine the PCSA in hematology during the TE period (from the first treatment administration up to the end of study). Here, Hb = hemoglobin; g/L = grams per liter; M = male; F = female; v/v= volume by volume; LC = leukocyte count; NB = non-black; B = black; ULN = upper limit of normal and EO = eosinophils. Only parameters in which any participant had abnormality are reported.

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Hematology During the Treatment-emergent Period
ParticipantsPart A: Former SmokersPart B: Current Smokers
Hb: >=185 g/ L (M); >=165 g/L (F)10
Hematocrit: >=0.55 v/v (M); >=0.5 v/v (F)12
LC: <3 x 10^9/ L (NB); <2 x 10^9/ L (B)10
Neutrophils: <1.5 x 10^9/ L (NB); <1 x 10^9/ L (B)10
Lymphocytes: >4 x 10^9/ L11
Monocytes: >0.7 x 10^9/ L910
Basophils: >0.1 x 10^9/ L43
EO: >0.5x10^9/ L or >ULN (ULN >=0.5x10^9/ L)01
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry During the Treatment-emergent Period

Blood samples were collected to determine the PCSA in chemistry during the TE period (first treatment administration up to the end of study). Here, mmol/L = millimoles/liter; LLN = lower limit of normal; mg/L = milligrams/liter and mcmol/L = micromoles/liter. Only parameters in which any participant had abnormality are reported.

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Chemistry During the Treatment-emergent Period
ParticipantsPart A: Former SmokersPart B: Current Smokers
Glucose: <=3.9 mmol/ L and <LLN20
Glucose: >=11.1 mmol/L (unfasted); >=7 mmol/L (fasted)33
Cholesterol: >=7.74 mmol/L02
C-reactive protein: >2 ULN or >10 mg/ L54
Potassium: >=5.5 mmol/L01
Creatinine: >=30% change from baseline25
Uric acid: >408 mcmol/L54
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period

Urine samples were collected to determine the PCSA in urine during the TE period (from the first treatment administration up to the end of study).

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period
ParticipantsPart A: Former SmokersPart B: Current Smokers
Number of Participants With Potentially Clinically Significant Abnormalities in Urinalysis During the Treatment-emergent Period00
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities in Vital Signs During the Treatment-emergent Period

Participants were examined to determine the PCSA in vital signs during the TE period (from the first treatment administration up to the end of study). Here, SSBP = sitting systolic blood pressure; mmHg = millimeters of mercury; DFB = decrease from baseline and IFB = increase from baseline. Only parameters in which any participant had abnormality are reported.

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs During the Treatment-emergent Period
ParticipantsPart A: Former SmokersPart B: Current Smokers
SSBP: <=95 mmHg and DFB>=20 mmHg01
SSBP: >=160 mmHg and IFB>=20 mmHg11
Weight: >=5% DFB60
Weight: >=5% IFB51
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) During the Treatment-emergent Period

Single 12-lead ECGs were obtained to determine PCSA during the TE period (from the first treatment administration up to the end of study). Here, QTcB= QT interval corrected by Bazett's formula and QTcF= QT interval corrected by Fridericia formula. Only parameters in which any participant had abnormality are reported.

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) During the Treatment-emergent Period
ParticipantsPart A: Former SmokersPart B: Current Smokers
Heart rate: >90 beats/minute21
Heart rate: >90 beats/minute and IFB>=20 beats/minute20
Heart rate: >100 beats/minute11
Heart rate: >100 beats/minute and IFB>=20 beats/minute10
PR interval, single beat: >200 milliseconds10
QRS duration, single beat: >110 milliseconds22
QRS duration, single beat: >120 milliseconds20
QT interval, single beat: >500 milliseconds01
QTcB interval, single beat: >450 milliseconds43
QTcB interval, single beat: >480 milliseconds02
QTcB interval, single beat: >500 milliseconds01
QTcB interval, single beat - change from baseline: IFB >=30-60 milliseconds20
QTcB interval, single beat - change from baseline: IFB >60 milliseconds01
QTcF interval, single beat: >450 milliseconds23
QTcF interval, single beat: >480 milliseconds01
QTcF interval, single beat: >500 milliseconds01
QTcF interval, single beat - change from baseline: IFB >60 milliseconds01
SecondaryNumber of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab

Blood samples were collected to evaluate antibodies to itepekimab in serum. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing.

Time frame:
From first dose of study treatment administration (Week 0) up to end of study, 32 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab
ParticipantsPart A: Former SmokersPart B: Current Smokers
Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) to Itepekimab10
SecondarySerum Concentrations of Functional Itepekimab

Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

Time frame:
Pre-dose at Weeks 0, 4, 12 and 32
Reported as:
Geometric mean · nanograms per milliliter
Serum Concentrations of Functional Itepekimab
nanograms per milliliterPart A: Former SmokersPart B: Current Smokers
Week 00.0 ± 0.000.0 ± 0.00
Week 436643.3 ± 30.9336237.8 ± 32.91
Week 1259936.6 ± 28.6961234.3 ± 39.83
Week 321631.7 ± 60.381597.3 ± 75.38

Adverse events

Collected over SAEs and other AEs were collected from first dose of study treatment administration (Week 0) up to end of study, i.e., up to 32 weeks. All-cause mortality (Deaths) was collected from first dose of study treatment administration (Week 0) up to end of follow-up for death for each participant, i.e. up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Former Smokers0/23 (0%)1/23 (4.3%)0/23 (0%)
Part B: Current Smokers0/24 (0%)2/24 (8.3%)0/24 (0%)
Most frequent serious events
Most frequent serious events
EventPart A: Former SmokersPart B: Current Smokers
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/232/24
DiverticulitisInfections and infestations1/230/24
Urinary Tract Infection BacterialInfections and infestations1/230/24

Baseline characteristics

The safety population included all enrolled participants who took at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Part A: Former SmokersPart B: Current SmokersTotal
Mean63.8 ± 4.660.0 ± 6.761.9 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Former SmokersPart B: Current SmokersTotal
Female10919
Male131528
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Former SmokersPart B: Current SmokersTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American000
White192443
More than one race101
Unknown or Not Reported101
Itepekimab Pharmacodynamic Normalized Enrichment Score (NES) in Endobronchial Biopsy
Itepekimab Pharmacodynamic Normalized Enrichment Score (NES) in Endobronchial Biopsy(score on a scale)Part A: Former SmokersPart B: Current SmokersTotal
Median0.203 (0.00 to 2.38)0.357 (0.00 to 1.23)0.295 (0.00 to 2.38)
Itepekimab Pharmacodynamic Normalized Enrichment Score in Bronchial Brushings
Itepekimab Pharmacodynamic Normalized Enrichment Score in Bronchial Brushings(score on a scale)Part A: Former SmokersPart B: Current SmokersTotal
Median0.719 (0.00 to 1.63)0.827 (0.26 to 2.38)0.813 (0.00 to 2.38)
Itepekimab Pharmacodynamic Normalized Enrichment Score in Nasal Brushings
Itepekimab Pharmacodynamic Normalized Enrichment Score in Nasal Brushings(score on a scale)Part A: Former SmokersPart B: Current SmokersTotal
Median1.620 (0.58 to 2.52)0.961 (0.27 to 2.24)1.175 (0.27 to 2.52)
08

Study locations

23 sites
  • UCLA Medical Center - Harbor- Site Number : 8400006
    Torrance, California 90509, United States
  • National Jewish Health Medical Center- Site Number : 8400012
    Denver, Colorado 80206, United States
  • University of Miami UHealth Tower- Site Number : 8400015
    Miami, Florida 33125, United States
  • University of Kansas Medical Center- Site Number : 8400004
    Kansas City, Missouri 66160, United States
  • Allergy, Asthma and Clinical Research- Site Number : 8400010
    Oklahoma City, Oklahoma 73120, United States
  • Clinical Research Associates of Central PA - Dubois- Site Number : 8400011
    DuBois, Pennsylvania 15801, United States
  • University of Texas - Southwestern Medical Center- Site Number : 8400014
    Dallas, Texas 75390, United States
  • Investigational Site Number : 0560001
    Edegem, 2650, Belgium
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital e Maternidade Celso Pierro - PUC-Campinas- Site Number : 0760004
    Campinas, São Paulo 13059-900, Brazil
  • Integral Pesquisa e Ensino- Site Number : 0760006
    Votuporanga, São Paulo 15501-405, Brazil
  • Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760005
    São Paulo, 01323-900, Brazil
  • Investigational Site Number : 2080003
    Aalborg, 9000, Denmark
  • Investigational Site Number : 2080001
    Copenhagen, 2400, Denmark
  • Investigational Site Number : 2080002
    Hvidovre, 2650, Denmark
  • Investigational Site Number : 2760005
    Freiburg im Breisgau, 79106, Germany
  • Investigational Site Number : 2760001
    Großhansdorf, 22926, Germany
  • Investigational Site Number : 2760004
    Peine, 31224, Germany
  • Investigational Site Number : 5280001
    Groningen, 9713 GZ, Netherlands
  • Investigational Site Number : 8260003
    Wythenshawe, Cheshire West And Chester M23 9QZ, United Kingdom
  • Investigational Site Number : 8260004
    London, London, City of W2 1NY, United Kingdom
  • Investigational Site Number : 8260001
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Investigational Site Number : 8260002
    Liverpool, L9 7AL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Mar 2025, 33 months.

Results were first posted in Aug 2026, 1 year 5 months after primary completion. A results delay was requested in Mar 2026.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 33 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 13, 2022
StartActual
May 19, 2022
Primary completionActual
Mar 5, 2025
CompletionActual
Jul 25, 2025
Results delay requested
Mar 3, 2026
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05326412
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
May 19, 2022
Primary completion
Mar 5, 2025
Completion
Jul 25, 2025
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion